| 14.8903 -0.64 (-4.12%) | 08-24 15:03 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.03 | 1-year : | 23.39 |
| Resists | First : | 17.14 | Second : | 20.03 |
| Pivot price | 14.53  |
|||
| Supports | First : | 14.24 | Second : | 12.44 |
| MAs | MA(5) : | 15.48 |
MA(20) : | 14.17 |
| MA(100) : | 16.54 |
MA(250) : | 19.32 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 57.6 |
D(3) : | 65.7 |
| RSI | RSI(14): 55.1 |
|||
| 52-week | High : | 45 | Low : | 10.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LYEL ] has closed below upper band by 35.1%. Bollinger Bands are 32.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.18 - 16.27 | 16.27 - 16.36 |
| Low: | 15.11 - 15.22 | 15.22 - 15.33 |
| Close: | 15.36 - 15.53 | 15.53 - 15.68 |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Tue, 11 Aug 2026
Lyell Immunopharma (LYEL) COO auto-sells 89 shares for RSU tax withholding - Stock Titan
Tue, 11 Aug 2026
Lyell Immunopharma (LYEL) CEO sells shares to cover RSU tax withholding - Stock Titan
Sat, 08 Aug 2026
Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - simplywall.st
Wed, 22 Jul 2026
Stifel initiates Lyell Immunopharma stock with buy, $44 target - Investing.com
Thu, 02 Jul 2026
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet - Yahoo Finance
Thu, 25 Jun 2026
LYEL Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -73 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 2.451e+007 (%) |
| Held by Institutions | 1.215e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 27000 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -12.69 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 183 % |
| Return on Equity (ttm) | 425 % |
| Qtrly Rev. Growth | -93.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.8094e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -1.19 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 1.23e+006 |
| Forward Dividend | 1.22e+006 |
| Dividend Yield | 8197270% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|